ES2533208T3 - Uso de una composición que contiene fosfolípidos y ácido glicirricínico par eliminar acumulaciones adiposas subcutáneas por medio de lipólisis subcutánea - Google Patents
Uso de una composición que contiene fosfolípidos y ácido glicirricínico par eliminar acumulaciones adiposas subcutáneas por medio de lipólisis subcutánea Download PDFInfo
- Publication number
- ES2533208T3 ES2533208T3 ES11716415.2T ES11716415T ES2533208T3 ES 2533208 T3 ES2533208 T3 ES 2533208T3 ES 11716415 T ES11716415 T ES 11716415T ES 2533208 T3 ES2533208 T3 ES 2533208T3
- Authority
- ES
- Spain
- Prior art keywords
- subcutaneous
- glycyrrhizinic acid
- composition containing
- eliminate
- lipolysis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Uso de una composición que contiene a) al menos un fosfolípido; b) ácido glicirricínico, o una sal de ácido glicirricínico y c) eventualmente, adyuvantes en donde - el contenido total de fosfolípidos y el ácido glicirricínico o sus sales es de 2 a 80% en peso, y - la proporción en peso entre los fosfolípidos y el ácido glicirricínico o sus sales es de 30:1 a 0,5:1 para la fabricación de un medicamento para el tratamiento terapéutico de enfermedades del tejido adiposo subcutáneo.
Description
----
=
- 7
- S.A. Cribado 3,2 3,3 31 32
- 0
- 3,2 3,3 31 32
- 8
- 2,8 2,9 27 28,5 Drl/DrlP Colesterol total de 212,0 mg/dl a 214,0 mg/dl Colesterol LDL de 104,0 mg/dl a 103,0 mg/dl Colesterol HDL de 88,4 mg/dl a 89,1 mg/dl
- 16
- 2,7 2,8 26 27 Drl/DrlP γ-GT normalizada Resistencia cutánea buena desde el inicio
- 1
- G.E. Cribado 3,8 3,8 33 33
- 0
- 3,8 3,8 33 33
- 8
- 3,2 3,2 31,8 31,8 Del/DelP Colesterol total de 143,0 mg/dl a 141,0 mg/dl Colesterol LDL de 53,0 mg/dl a 51,0 mg/dl Colesterol HDL de 67,0 mg/dl a 68,0 mg/dl
- 16
- 2,8 2,8 30,5 30,5 Del/DelP Colesterol total de 141,0 mg/dl a 142,0 mg/dl Colesterol LDL de 51,0 mg/dl a 49,0 mg/dl Colesterol HDL de 68,0 mg/dl a 54,0 mg/dl Resistencia cutánea buena desde el inicio
Del = mejoría definitiva de eficacia y compatibilidad, médico; DelP = mejoría definitiva de eficacia y compatibilidad, paciente; Drl = mejoría notable de eficacia y compatibilidad, médico; DrlP = mejoría notable de eficacia y compatibilidad, paciente
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102010028365 | 2010-04-29 | ||
| DE102010028365A DE102010028365A1 (de) | 2010-04-29 | 2010-04-29 | Verwendung einer Phospholipid enthaltenden Zusammensetzung zur Entfernung von subkutanen Fettansammlungen |
| PCT/EP2011/056721 WO2011135020A1 (de) | 2010-04-29 | 2011-04-28 | Verwendung einer phospholipid und glycyrrhizinsäure enthaltenden zusammensetzung zur entfernung von subkutanen fettansammlungen durch subkutane lipolyse |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2533208T3 true ES2533208T3 (es) | 2015-04-08 |
Family
ID=44065304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11716415.2T Active ES2533208T3 (es) | 2010-04-29 | 2011-04-28 | Uso de una composición que contiene fosfolípidos y ácido glicirricínico par eliminar acumulaciones adiposas subcutáneas por medio de lipólisis subcutánea |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9399042B2 (es) |
| EP (1) | EP2563370B1 (es) |
| JP (1) | JP2013525407A (es) |
| KR (1) | KR20130118733A (es) |
| CN (1) | CN102970993A (es) |
| AR (1) | AR080970A1 (es) |
| BR (1) | BR112012027550A2 (es) |
| DE (1) | DE102010028365A1 (es) |
| ES (1) | ES2533208T3 (es) |
| MX (1) | MX2012012604A (es) |
| RU (1) | RU2549966C2 (es) |
| TW (1) | TW201143778A (es) |
| WO (1) | WO2011135020A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101545706B1 (ko) * | 2013-05-10 | 2015-08-26 | 주식회사 아미팜 | 포스파티딜콜린을 포함하는 지방 분해용 조성물 및 이의 제조방법 |
| KR102146667B1 (ko) * | 2014-06-27 | 2020-08-21 | (주)메디톡스 | 지방 감소를 위한 담즙산 및 염의 방법 및 조성물 |
| KR101760685B1 (ko) * | 2014-09-26 | 2017-08-04 | 연천군 | 위암 예방용 건강기능성 식품 |
| US9855216B2 (en) | 2015-05-27 | 2018-01-02 | Ghasem Amoabediny | Targeted nano-liposome co-entrapping anti-cancer drugs |
| EP3124047A1 (en) | 2015-07-28 | 2017-02-01 | Merz Pharma GmbH & Co. KGaA | Pentacyclic triterpenoids for injection lipolysis |
| RU2725622C1 (ru) * | 2019-10-30 | 2020-07-03 | Открытое акционерное общество "Фармстандарт-Лексредства" (ОАО "Фармстандарт-Лексредства") | Фармацевтическая композиция для лечения и/или профилактики заболеваний печени |
| EA202090511A1 (ru) | 2020-03-13 | 2021-09-30 | ДИКОВСКИЙ, Александр Владимирович | Композиция для нормализации уровня липидов в крови |
| KR102543754B1 (ko) * | 2021-09-15 | 2023-06-14 | 김민경 | 지방분해용 주사제 조성물 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3047011A1 (de) | 1980-12-13 | 1982-07-22 | A. Nattermann & Cie GmbH, 5000 Köln | Verfahren zur abtrennung von oel und/oder phosphatidylethanolamin aus diese enthaltenden alkoholloeslichen phosphatidylcholin-produkten |
| DE3047048A1 (de) | 1980-12-13 | 1982-07-29 | A. Nattermann & Cie GmbH, 5000 Köln | Verfahren zur abtrennung von oel und/oder phosphatidylethanolamin aus diese enthaltenden alkoholloeslichen phosphatidylcholin-produkten |
| DE3887494T2 (de) | 1987-11-13 | 1994-05-19 | Smithkline Beecham Farma | Ein Calcitonin sowie ein Glycyrrhizinat als Absorptionsförderer enthaltende Arzneimittel. |
| ES2076203T3 (es) * | 1988-12-22 | 1995-11-01 | Kanebo Ltd | Composicion cosmetica. |
| JP2911496B2 (ja) | 1989-09-11 | 1999-06-23 | 帝國製薬株式会社 | 生理活性ポリペプチド含有高吸収性経膣剤 |
| DE4122744C2 (de) | 1990-08-06 | 1994-02-03 | Nattermann A & Cie | Wäßriges Liposomensystem und Verfahren zu seiner Herstellung |
| DE4308121A1 (de) | 1993-03-15 | 1994-09-22 | Rhone Poulenc Rorer Gmbh | Wäßriges Liposomensystem sowie Verfahren zur Herstellung eines derartigen Liposomensystems |
| RU2133122C1 (ru) | 1998-10-14 | 1999-07-20 | Научно-исследовательский институт биомедицинской химии РАМН | Композиция, обладающая свойствами репарировать биологические мембраны |
| DE10062610A1 (de) | 2000-12-15 | 2002-06-27 | Merz & Co Gmbh & Co | Vesikelbildende Hautöle aus öllöslichen Komponenten und W/O-Emulgatoren nit einem HLB-Wert von 2-6 und vesikelbildenden Lipiden sowie wahlweise einem oder mehreren üblichen Zusatzstoffen, Verfahren zu deren Herstellung und ihre Verwendung |
| JP3615510B2 (ja) | 2001-03-27 | 2005-02-02 | 日華化学株式会社 | リパーゼ活性賦活剤、痩身用皮膚外用剤及び痩身用浴用剤 |
| DE10324256B4 (de) | 2003-05-28 | 2010-04-22 | Merz Pharma Gmbh & Co. Kgaa | Lipid-Tranferprotein-Systeme und deren kosmetische/dermatologische Anwendung |
| DE10348554A1 (de) | 2003-10-20 | 2005-05-19 | Symrise Gmbh & Co. Kg | Verwendung einer Verbindung aus der Gruppe der Heterodiazole oder eines Salzes der Verbindung, die Verbindung oder das Salz enthaltende kosmetische oder therapeutische Formulierung, die Verbindung oder das Salz als therapeutisches Mittel sowie das Salz selbst |
| DE10349979B4 (de) | 2003-10-24 | 2006-05-18 | Sanofi-Aventis Deutschland Gmbh | Medikamentöse gezielte lokale Lipolyse |
| US20050089555A1 (en) | 2003-10-24 | 2005-04-28 | Aventis Pharma Deutschland Gmbh | Medicinal targeted local lipolysis |
| DE10361067A1 (de) | 2003-12-22 | 2005-07-14 | Aventis Pharma Deutschland Gmbh | Medikamentöse Lipolyse von Fettansammlungen |
| US20050143347A1 (en) | 2003-12-22 | 2005-06-30 | Aventis Pharma Deutschland Gmbh | Medicinal lipolysis of accumulations of fat |
| JP2006137670A (ja) | 2004-11-10 | 2006-06-01 | Pola Chem Ind Inc | ヘアトニック |
| DE102004057150A1 (de) | 2004-11-26 | 2006-06-14 | Merz Pharma Gmbh & Co. Kgaa | Topisch applizierbare Zubereitungen, enthaltend eine Kombination aus einem biokatalytischen Mehrphasensystem und einem Kapillar-Wirksystem, sowie dessen Anwendung |
| RU2283114C1 (ru) * | 2005-06-07 | 2006-09-10 | Открытое акционерное общество "Нижегородский химико-фармацевтический завод" | Композиция, обладающая гепатопротекторной активностью и нормализующая обменные процессы |
| RU2304430C2 (ru) | 2005-08-12 | 2007-08-20 | Александр Иванович Арчаков | Способ получения инъекционной лекарственной формы фосфолипидного препарата "фосфоглив" для лечения и профилактики острых и хронических заболеваний печени |
| RU2304431C2 (ru) * | 2005-08-12 | 2007-08-20 | Александр Иванович Арчаков | Способ получения капсулированной лекарственной формы фосфолипидного препарата "фосфоглив" для лечения и профилактики острых и хронических заболеваний печени |
| JP5047507B2 (ja) | 2005-09-30 | 2012-10-10 | 昭和電工株式会社 | カルニチン誘導体及びその塩、皮膚外用剤ならびに化粧料 |
| DE102005056538A1 (de) | 2005-11-28 | 2007-05-31 | Merz Pharma Gmbh & Co. Kgaa | Zusammensetzungen, enthaltend Proteine zum Transfer / Recycling strukturell veränderter Lipide aus Biomembranen, sowie deren Anwendungen |
| EP1923041A1 (de) | 2006-10-20 | 2008-05-21 | Symrise GmbH & Co. KG | Verwendung von C10-C14-Alkandiolen zur Herstellung eines Mittels zur Prophylaxe und/oder Behandlung von Malassezia-induzierter Schuppenbildung, sowie Zubereitungen enthaltend C10-C14-Alkandiole |
| EP1915982A1 (de) | 2006-10-20 | 2008-04-30 | Symrise GmbH & Co. KG | Verwendung von 1,2-Decandiol zur Sebumreduktion bzw. zur Unterstützung des Eindringens von Wirkstoffen in Hautbereiche, sowie kosmetische und/oder dermatologische Zubereitungen umfassend 1,2-Decandiol |
| DE102007015701A1 (de) | 2007-03-19 | 2008-09-25 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh | Neue pharmazeutische Zusammensetzungen für die Lipolyse und Verfahren zu deren Herstellung |
| JPWO2008143182A1 (ja) * | 2007-05-17 | 2010-08-05 | 株式会社カネカ | 甘草ポリフェノールを含有する組成物 |
| JP2009242354A (ja) | 2008-03-31 | 2009-10-22 | Kobayashi Pharmaceut Co Ltd | 医薬組成物 |
| RU2373924C1 (ru) * | 2008-04-14 | 2009-11-27 | Учреждение Российской академии медицинских наук Научно-исследовательский институт биомедицинской химии им.В.Н.Ореховича РАМН (ИБМХ РАМН), RU | Наноформа фосфолипидного препарата для перорального применения и способ ее получения |
-
2010
- 2010-04-29 DE DE102010028365A patent/DE102010028365A1/de not_active Withdrawn
-
2011
- 2011-04-26 AR ARP110101436A patent/AR080970A1/es unknown
- 2011-04-28 CN CN2011800237863A patent/CN102970993A/zh active Pending
- 2011-04-28 BR BR112012027550-0A patent/BR112012027550A2/pt not_active Application Discontinuation
- 2011-04-28 EP EP11716415.2A patent/EP2563370B1/de active Active
- 2011-04-28 WO PCT/EP2011/056721 patent/WO2011135020A1/de not_active Ceased
- 2011-04-28 US US13/642,916 patent/US9399042B2/en active Active
- 2011-04-28 RU RU2012151147/15A patent/RU2549966C2/ru active
- 2011-04-28 ES ES11716415.2T patent/ES2533208T3/es active Active
- 2011-04-28 KR KR1020127031378A patent/KR20130118733A/ko not_active Withdrawn
- 2011-04-28 TW TW100114826A patent/TW201143778A/zh unknown
- 2011-04-28 JP JP2013506657A patent/JP2013525407A/ja active Pending
- 2011-04-28 MX MX2012012604A patent/MX2012012604A/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP2563370A1 (de) | 2013-03-06 |
| BR112012027550A2 (pt) | 2018-02-06 |
| RU2549966C2 (ru) | 2015-05-10 |
| KR20130118733A (ko) | 2013-10-30 |
| MX2012012604A (es) | 2013-02-26 |
| AR080970A1 (es) | 2012-05-23 |
| US20130157967A1 (en) | 2013-06-20 |
| DE102010028365A1 (de) | 2011-11-03 |
| WO2011135020A1 (de) | 2011-11-03 |
| CN102970993A (zh) | 2013-03-13 |
| US9399042B2 (en) | 2016-07-26 |
| JP2013525407A (ja) | 2013-06-20 |
| TW201143778A (en) | 2011-12-16 |
| EP2563370B1 (de) | 2014-12-17 |
| RU2012151147A (ru) | 2014-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2533208T3 (es) | Uso de una composición que contiene fosfolípidos y ácido glicirricínico par eliminar acumulaciones adiposas subcutáneas por medio de lipólisis subcutánea | |
| Vercruysse Jr et al. | Outcomes of osseous free flap reconstruction in stage III bisphosphonate-related osteonecrosis of the jaw: systematic review and a new case series | |
| BR112014031788A2 (pt) | composições e métodos para o tratamento de diabetes | |
| AR086356A1 (es) | Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2 | |
| ES2521674T3 (es) | Métodos de tratamiento de hiperuricemia y estados patológicos asociados | |
| AR082803A1 (es) | Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p | |
| Oizumi et al. | A strategy against the osteonecrosis of the jaw associated with nitrogen-containing bisphosphonates (N-BPs): attempts to replace N-BPs with the non-N-BP etidronate | |
| Ribeiro et al. | Oral cysticercosis: Case report | |
| Dutra et al. | Prevalent nursing diagnosis in patients hospitalized with sepsis at the intensive care unit | |
| CO6491041A2 (es) | Otamixaban para el tratamiento de pacientes con alteracion renal y de edad avanzada con infarto de miocardio sin elevancion del st | |
| Weeda Jr | Goodbye BRONJ… Hello MRONJ | |
| Gorecki et al. | Implication of bisphosphonate use in the treatment of SAPHO syndrome: case report and discussion of current literature | |
| Biehler-Gomez et al. | How do skeletons with HIV present? A study on the identified CAL Milano Cemetery Skeletal Collection | |
| AR072120A1 (es) | Fenil-alquil-piperazinas que tienen actividad moduladora de tnf, un proceso de preparacion del compuesto, una composicion farmaceutica que lo contiene, un medicamento en base al compuesto y la utilizacion del compuesto para preparar un medicamento | |
| Lazăr et al. | Retrospective study regarding the appearance of osteonecrosis related to bisphosphonate therapy | |
| Valizadeh | Imatinib induced facial skin hyperpigmentation in a case of chronic myelogenous leukemia | |
| David-West | Intraosseous lipoma of the calcaneus | |
| Олійник et al. | Diagnostic Monitoring of Periimplant Tissues and its Adequate Optimization | |
| Garcia et al. | SCLEROTHERAPY OF VASCULAR LESIONS IN ORAL AND MAXILLOFACIAL REGION—CASE SERIES | |
| Brown et al. | Estrin therapy in a case of hemophilia | |
| Suárez et al. | Toracotomía en el Servicio de Urgencias | |
| Franzoi et al. | ORAL SQUAMOUS CELL CARCINOMA WITH MANDIBULAR BONE INVASION: CASE REPORT | |
| Eastley et al. | 99. Nationwide trends in the current management of desmoid (aggressive) fibromatosis | |
| Rohan et al. | Frailty Index: A Useful Stratification for Elderly Surgical Patients | |
| Zhussupov et al. | Modified spherical curette for maxilla sinus mycetoma ablation |